Tuesday, September 26, 2023


Biotechnology News Magazine

Antimicrobial Market Plagued with Toxic Substances — Advises Additive Expert

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

New test results demonstrate Saniconcentrate™, an additive technology patented by Parx Materials, reduces Covid-19 virus on surfaces by up to 99 percent in 24 hours.

Unlike other antimicrobial options, it achieves this without biocides, leaching, or harmful side effects, creating a breakthrough option for applications like touch surfaces in public areas, medical devices, or food contact applications. This proves Saniconcentrate™ will be a strong and safe tool in preventing the spread of viruses in the future.

With Saniconcentrate™, Parx Materials has created a way to make plastic intrinsically resistant to bacteria and viruses. The additive is homogenously incorporated into plastics to create an ’immune system’ inherent to the material.

Antimicrobial technologies have historically used biocides, such as silver or copper, to destroy microorganisms. While this method may effectively destroy bacteria and viruses, it can lead to toxic substances leaching out of the material, contaminating the products or surfaces it is trying to protect, as well as contaminating the environment and making recycling a more challenging task. In addition to relying on finite resources to work, bacteria and viruses tend to become resistant to biocides over time, reducing the biocides’ efficacy. Making bacteria viruses stronger so they become more difficult to battle and cause a bigger threat in the future.

Typically, bacteria and viruses attach to surfaces in order to sustain themselves over a long period of time. Inspired by the defense mechanisms of the human body, the technology of Parx Materials works by mimicking the physical characteristics of the human skin.

Saniconcentrate™ uses a trace element abundantly found in the body to prevent bacteria and viruses from adhering to surfaces, causing them to run through their usual lifecycle and die within hours. This ecological approach of dealing with germs can be seen as a natural way to keep bacteria and viruses at bay, instead of just killing them and inducing resistance.

As Saniconcentrate™ uses materials already found in the human body, it is biocompatible, safe and its applications are limitless. The technology is currently in use in major supermarkets and has shown outstanding results in medical trials.

A new study, carried out by an authorized laboratory, identifies the development of the amount of Covid-19 virus on plastic surfaces made with the Saniconcentrate™ additive. The test was carried out in accordance with ISO 21702:2019 “measurement of antiviral activity on plastics and other non-porous surfaces”. After 24 hours, the treated sample saw a 99 percent reduction in the virus.

PRX001 graph

A second test on a different material made with Saniconcentrate™, found a 53.23 percent reduction in Covid-19 virus after just six hours and a 93.24 percent reduction after 24 hours. This proves definitively that Saniconcentrate™ protects surfaces against coronavirus and therefore its spread. Here, Covid-19 and coronavirus refer to the SARS-CoV-2 virus; the tests were carried out using the COV2019 Italy/INMI1 strain.

Michal van der Jagt“Today’s struggles against the Covid-19 pandemic and antibiotic-resistant superbugs show that innovation is needed when it comes to antimicrobial materials,” commented Michaël van der Jagt, CEO of Parx Materials. “The test results showing a 99 percent reduction in coronavirus on Saniconcentrate™ treated surfaces confirms its ability to help us return to normal life using a safe and ecological approach.”

Parx Materials is currently looking for investment to further accelerate its scale-up.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine